5' UTR Gene Knock-In Therapy for Retinitis Pigmentosa
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for autosomal dominant disorders, such as retinitis pigmentosa, face challenges due to off-target effects and limited versatility in addressing high mutation heterogeneity, particularly in treating diseases like retinitis pigmentosa with numerous disease-causing genes and diverse mutations.
Innovation Solution
The development of novel 5' untranslated region (UTR)-targeting gene knock-in (KI) compositions and methods that utilize homology-independent targeted integration (HITI) to insert a wild-type coding sequence into the 5' UTR upstream of a translation initiation element, allowing for efficient and precise correction of mutated genes without requiring mutation-specific strategies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mutation-specific knockdown or knockout approaches are used to treat autosomal dominant disorders, then therapeutic specificity is improved, but off-target effects increase and versatility decreases
Solution Approach 1:
The patent extracts the therapeutic action from the mutated coding sequence and relocates it to the 5' UTR region. By placing the wild-type coding sequence in the 5' UTR upstream of the mutated gene's translation initiation element, the wild-type protein is expressed independently without requiring disruption of the mutated allele, thereby eliminating off-target effects while maintaining therapeutic specificity.
Solution Approach 2:
The 5' UTR serves as an intermediary region that mediates the expression of the wild-type coding sequence without directly interacting with the mutated coding sequence. This intermediary approach allows the wild-type protein to be produced while the mutated allele remains intact but non-expressive, avoiding the need for direct knockout or knockdown that causes off-target effects.
2Manufacturing precision
If base editing or prime editing is used to repair disease alleles, then precision is improved, but versatility for high mutation heterogeneity decreases
Solution Approach 1:
The patent creates a universal therapeutic approach that works across multiple mutation types by targeting the 5' UTR region rather than specific coding sequence mutations. The method can address both loss-of-function and gain-of-function mutations, as well as various inheritance patterns (autosomal dominant, recessive, X-linked), making it versatile for high mutation heterogeneity while maintaining precision through targeted integration.
Solution Approach 2:
Instead of attempting to repair the mutated coding sequence directly (the conventional approach), the patent inverts the strategy by inserting a wild-type coding sequence into the 5' UTR region. This inversion allows the wild-type sequence to be expressed without needing to correct the specific mutation in the original coding sequence, thereby achieving precision and versatility simultaneously.
3Reliability
If RNA interference is used for allele-specific knockdown, then mutation-specific targeting is improved, but off-target effects and limited availability of PAM sites worsen the approach
Solution Approach 1:
The patent extracts the therapeutic function from the coding sequence and places it in the 5' UTR, eliminating the need for PAM sites that are required for CRISPR-based RNA interference approaches. This extraction allows allele-specific targeting without the constraints of PAM site availability and reduces the complexity associated with finding suitable PAM sites near each mutation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach demonstrates enhanced safety and efficiency in inserting wild-type genes, inhibiting expression of mutated variants, and prolonging photoreceptor survival and visual function, offering a promising treatment for autosomal dominant disorders like retinitis pigmentosa.
Implementation Method 1
the nuclease causes a break within a 5′ UTR of an endogenous nucleic acid encoding a mutated variant of the wild-type gene
Implementation Method 2
the exogenous nucleic acid encoding the knock-in cassette is integrated by homology-independent targeted integration into the 5′ UTR of the endogenous nucleic acid upstream (5′) of the translation initiation element
Data Source
AI summary
Novel 5′ untranslated region (UTR)-targeting gene knock-in (KI) compositions and methods of use are disclosed. The gene KI compositions and methods exploit homology-independent targeted integration (HITI)-mediated insertion of a wild-type coding sequence (CDS) into the 5′ UTR upstream of a translation initiation element of a mutated variant of the wild-type gene. The 5′ UTR-targeting gene KI therapy compositions and methods provide safer and more efficient gene insertion compared to other gene therapy approaches.